• Something wrong with this record ?

Computational Prodrug Design Methodology for Liposome Formulability Enhancement of Small-Molecule APIs

M. Balouch, K. Storchmannová, F. Štěpánek, K. Berka

. 2023 ; 20 (4) : 2119-2127. [pub] 20230320

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Encapsulation into liposomes is a formulation strategy that can improve efficacy and reduce side effects of active pharmaceutical ingredients (APIs) that exhibit poor biodistribution or pharmacokinetics when administered alone. However, many APIs are unsuitable for liposomal formulations intended for parenteral administration due to their inherent physicochemical properties─lipid bilayer permeability and water-lipid equilibrium partitioning coefficient. Too high permeability results in premature leakage from liposomes, while too low permeability means the API is not able to pass across biological barriers. There are several options for solving this issue: (i) change of the lipid bilayer composition, (ii) addition of a permeability enhancer, or (iii) modification of the chemical structure of the API to design a prodrug. The latter approach was taken in the present work, and the effect of small changes in the molecular structure of the API on its permeation rate across a lipidic bilayer was systematically explored utilizing computer simulations. An in silico methodology for prodrug design based on the COSMOperm approach has been proposed and applied to four APIs (abiraterone, cytarabine, 5-fluorouracil, and paliperidone). It is shown that the addition of aliphatic hydrocarbon chains via ester or amide bonds can render the molecule more lipophilic and increase its permeability by approximately 1 order of magnitude for each 2 carbon atoms added, while the formation of fructose adducts can provide a more hydrophilic character to the molecule and reduce its lipid partitioning. While partitioning was found to depend only on the size and type of the added group, permeability was found to depend also on the added group location. Overall, it has been shown that both permeability and lipid partitioning coefficient can be systematically shifted into the desired liposome formulability window by appropriate group contributions to the parental drug. This can significantly increase the portfolio of APIs for which liposome or lipid nanoparticle formulations become feasible.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010503
003      
CZ-PrNML
005      
20230801132451.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.molpharmaceut.2c01078 $2 doi
035    __
$a (PubMed)36939094
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Balouch, Martin $u Department of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 3, 166 28 Prague 6, Czech Republic
245    10
$a Computational Prodrug Design Methodology for Liposome Formulability Enhancement of Small-Molecule APIs / $c M. Balouch, K. Storchmannová, F. Štěpánek, K. Berka
520    9_
$a Encapsulation into liposomes is a formulation strategy that can improve efficacy and reduce side effects of active pharmaceutical ingredients (APIs) that exhibit poor biodistribution or pharmacokinetics when administered alone. However, many APIs are unsuitable for liposomal formulations intended for parenteral administration due to their inherent physicochemical properties─lipid bilayer permeability and water-lipid equilibrium partitioning coefficient. Too high permeability results in premature leakage from liposomes, while too low permeability means the API is not able to pass across biological barriers. There are several options for solving this issue: (i) change of the lipid bilayer composition, (ii) addition of a permeability enhancer, or (iii) modification of the chemical structure of the API to design a prodrug. The latter approach was taken in the present work, and the effect of small changes in the molecular structure of the API on its permeation rate across a lipidic bilayer was systematically explored utilizing computer simulations. An in silico methodology for prodrug design based on the COSMOperm approach has been proposed and applied to four APIs (abiraterone, cytarabine, 5-fluorouracil, and paliperidone). It is shown that the addition of aliphatic hydrocarbon chains via ester or amide bonds can render the molecule more lipophilic and increase its permeability by approximately 1 order of magnitude for each 2 carbon atoms added, while the formation of fructose adducts can provide a more hydrophilic character to the molecule and reduce its lipid partitioning. While partitioning was found to depend only on the size and type of the added group, permeability was found to depend also on the added group location. Overall, it has been shown that both permeability and lipid partitioning coefficient can be systematically shifted into the desired liposome formulability window by appropriate group contributions to the parental drug. This can significantly increase the portfolio of APIs for which liposome or lipid nanoparticle formulations become feasible.
650    12
$a liposomy $x chemie $7 D008081
650    12
$a prekurzory léčiv $x chemie $7 D011355
650    _2
$a tkáňová distribuce $7 D014018
650    _2
$a lipidové dvojvrstvy $x chemie $7 D008051
650    _2
$a fluoruracil $7 D005472
650    _2
$a permeabilita $7 D010539
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Storchmannová, Kateřina $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic
700    1_
$a Štěpánek, František $u Department of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 3, 166 28 Prague 6, Czech Republic $1 https://orcid.org/0000000192884568 $7 mzk2012703367
700    1_
$a Berka, Karel $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic $1 https://orcid.org/0000000194722589 $7 ola2015878473
773    0_
$w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 20, č. 4 (2023), s. 2119-2127
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36939094 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132448 $b ABA008
999    __
$a ok $b bmc $g 1963118 $s 1196768
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 20 $c 4 $d 2119-2127 $e 20230320 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...